首页> 外文期刊>Translational psychiatry. >Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome
【24h】

Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome

机译:MeCP2对 MET 受体酪氨酸激酶基因的转录调控及自闭症和Rett综合征的性别特异性表达

获取原文
           

摘要

Single nucleotide variants (SNV) in the gene encoding the MET receptor tyrosine kinase have been associated with an increased risk for autism spectrum disorders (ASD). The MET promoter SNV rs1858830 C ‘low activity’ allele is enriched in ASD, associated with reduced protein expression, and impacts functional and structural circuit connectivity in humans. To gain insight into the transcriptional regulation of MET on ASD-risk etiology, we examined an interaction between the methyl CpG-binding protein 2 (MeCP2) and the MET 5′ promoter region. Mutations in MeCP2 cause Rett syndrome (RTT), a predominantly female neurodevelopmental disorder sharing some ASD clinical symptoms. MeCP2 binds to a region of the MET promoter containing the ASD-risk SNV, and displays rs1858830 genotype-specific binding in human neural progenitor cells derived from the olfactory neuroepithelium. MeCP2 binding enhances MET expression in the presence of the rs1858830 C allele, but MET transcription is attenuated by RTT-specific mutations in MeCP2. In the postmortem temporal cortex, a region normally enriched in MET , gene expression is reduced dramatically in females with RTT, although not due to enrichment of the rs1858830 C ‘low activity’ allele. We newly identified a sex-based reduction in MET expression, with male ASD cases, but not female ASD cases compared with sex-matched controls. The experimental data reveal a prominent allele-specific regulation of MET transcription by MeCP2. The mechanisms underlying the pronounced reduction of MET in ASD and RTT temporal cortex are distinct and likely related to factors unique to each disorder, including a noted sex bias.
机译:编码MET受体酪氨酸激酶的基因中的单核苷酸变异(SNV)与自闭症谱系障碍(ASD)的风险增加有关。 MET启动子SNV rs1858830 C“低活性”等位基因富含ASD,与蛋白质表达降低相关,并影响人类的功能和结构电路连通性。为了深入了解MET对ASD危险病因的转录调控,我们研究了甲基CpG结合蛋白2(MeCP2)与MET 5'启动子区域之间的相互作用。 MeCP2中的突变会引起Rett综合征(RTT),这是一种女性神经发育障碍,共有一些ASD临床症状。 MeCP2与包含ASD风险SNV的MET启动子区域结合,并在源自嗅觉神经上皮的人神经祖细胞中显示rs1858830基因型特异性结合。在rs1858830 C等位基因的存在下,MeCP2结合增强了MET的表达,但MeCP2中的RTT特异性突变减弱了MET的转录。在死后颞叶皮质中,通常富含MET的区域,RTT雌性中的基因表达显着降低,尽管不是由于rs1858830 C“低活性”等位基因的富集。我们新发现与性别匹配的对照组相比,男性ASD病例的MET表达基于性别的降低,而女性ASD病例则没有。实验数据显示MeCP2对MET转录具有突出的等位基因特异性调控。 ASD和RTT颞叶皮质MET明显减少的潜在机制是不同的,并且可能与每种疾病所特有的因素有关,包括明显的性别偏见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号